Back to Search
Start Over
High-Dose Osimertinib for CNS progression in EGFR+ NSCLC: A Multi-Institutional Experience
- Source :
- JTO Clinical and Research Reports; 20220101, Issue: Preprints
- Publication Year :
- 2022
-
Abstract
- This multicenter review evaluated the efficacy and safety of osimertinib dose-escalation for CNS progression developing on osimertinib 80 mg in EGFR-mutant NSCLC.
Details
- Language :
- English
- ISSN :
- 26663643
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- JTO Clinical and Research Reports
- Publication Type :
- Periodical
- Accession number :
- ejs59490371
- Full Text :
- https://doi.org/10.1016/j.jtocrr.2022.100328